Study of Bupropion for African American Light Smokers
Author Information
Author(s): Lisa Sanderson Cox, Babalola Faseru, Matthew S Mayo, Ron Krebill, Tricia S Snow, Carrie A Bronars, Nicole L Nollen, Wonsuk Choi, Kolawole S Okuyemi, Gary A Salzman, Neal L Benowitz, Rachel F Tyndale, Jasjit S Ahluwalia
Primary Institution: University of Kansas Medical Center
Hypothesis
Can bupropion effectively aid smoking cessation in African American light smokers?
Conclusion
The study demonstrated the feasibility of recruiting African American light smokers for a clinical trial involving genetic analysis and showed high motivation among participants to quit smoking.
Supporting Evidence
- Participants had a mean age of 46.5 years and 66.1% were women.
- Participants smoked an average of 8.0 cigarettes per day.
- 72.2% of participants smoked within 30 minutes of waking.
Takeaway
This study looked at how a medicine called bupropion can help African American light smokers stop smoking. It found that many people wanted to quit and were willing to participate in the study.
Methodology
Participants were randomly assigned to receive either bupropion or a placebo for 7 weeks, along with health education counseling.
Limitations
The study primarily included low-income African American light smokers, which may limit generalizability to other populations.
Participant Demographics
{"mean_age":46.5,"percentage_women":66.1,"percentage_smoking_menthol":83.7,"percentage_low_income":60.7}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website